A novel pharmacologic activity of ketorolac for therapeutic benefit in ovarian cancer patients

Clinical Cancer Research

Volumn 21, Issue 22, 2015, Pages 5064-5072

  Guo, Yuna ^a,b   Kenney, S Ray ^c   Cook, Linda ^a,b   Adams, Sarah F ^a,b   Rutledge, Teresa ^a,b   Romero, Elsa ^a   Oprea, Tudor I ^b   Sklar, Larry A ^a,b   Bedrick, Edward ^a,b,d   Wiggins, Charles L ^a,b   Kang, Huining ^a,b   Lomo, Lesley ^a,b   Muller, Carolyn Y ^a,b   Wandinger Ness, Angela ^a,b   Hudson, Laurie G ^b,c  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANOSINE TRIPHOSPHATASE; KETOROLAC; PROTEIN CDC42; RAC1 PROTEIN; KETOROLAC TROMETAMOL; PACLITAXEL; RAC1 PROTEIN, HUMAN;

ADULT; AGED; ANALGESIC ACTIVITY; ARTICLE; CANCER MORTALITY; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG PERITONEAL FLUID LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MEDICAL RECORD REVIEW; PERIOPERATIVE PERIOD; PERITONEAL CAVITY; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RACEMIC MIXTURE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; OVARIAN NEOPLASMS; PATHOLOGY;

AGED; CDC42 GTP-BINDING PROTEIN; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KETOROLAC; KETOROLAC TROMETHAMINE; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; RAC1 GTP-BINDING PROTEIN;

EID: 84946818704     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0461     Document Type: Article

References (50)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Jayson GC, Kohn EC, Kitchener HC, Lederman JA. Ovarian Cancer. Lancet 2014;384:1376-88.
3. Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek J, Brenton JD, et al. Rethinking ovarian cancer: Recommendations for improving outcomes. Nat Rev Cancer 2011;11:719-25.
4. Hall A. Rho family GTPases. Biochem Soc Trans 2012;40:1378-82.
5. Lawson CD, Burridge K. The on-off relationship of Rho and Rac during integrin-mediated adhesion and cell migration. Small GTPases 2014;7:5 [Epub ahead of print].
6. Heasman SJ, Ridley AJ. Mammalian Rho GTPases: New insights into their functions from in vivo studies. Nat Rev Mol Cell Biol 2008;9:690-701.
7. Karlsson R, Pedersen ED, Wang Z, Brakebusch C. Rho GTPase function in tumorigenesis. Biochim Biophys Acta 2009;1796:91-8.
8. Stengel K, Zheng Y. Cdc42 in oncogenic transformation, invasion, and tumorigenesis. Cell Signal 2011;23:1415-23.
9. Mack NA, Whalley HJ, Castillo-Lluva S, Malliri A. The diverse roles of Rac signaling in tumorigenesis. Cell Cycle 2011;10:1571-81.
10. Vega FM, Ridley AJ. Rho GTPases in cancer cell biology. FEBS Lett 2008;582:2093-101.
11. Bid HK, Roberts RD, Manchanda PK, Houghton PJ. RAC1: An emerging therapeutic option for targeting cancer angiogenesis and metastasis. Mol Cancer Ther 2013;12:1925-34.
12. Mardilovich K, Olson MF, Baugh M. Targeting Rho GTPase signaling for cancer therapy. Future Oncol 2012;8:165-77.
13. Zins K, Gunawardhana S, Lucas T, Abraham D, Aharinejad S. Targeting Cdc42 with the small molecule drug AZA197 suppresses primary colon cancer growth and prolongs survival in a preclinical mouse xenograft model by downregulation of PAK1 activity. J Transl Med 2013;11:295.
14. Zins K, Lucas T, Reichl P, Abraham D, Aharinejad S. A Rac1/Cdc42 GTPasespecific small molecule inhibitor suppresses growth of primary human prostate cancer xenografts and prolongs survival in mice. PLoS ONE 2013;11;e74924.
15. Friesland A, Zhao Y, Chen YH, Wang L, Zhou H, Lu Q. Small molecule targeting Cdc42-intersectin interaction disrupts Golgi organization and suppresses cell motility. Proc Natl Acad Sci U S A 2013;110:1261-6.
16. Montalvo-Ortiz BL, Castillo-Pichardo L, Hern-andez E, Humphries-Bickley T, De La Mota-Peynado A, Cubano LA, et al. Characterization of EHop-016, novel small-molecule inhibitor of Rac GTPase. J Biol Chem 2012;287: 13228-38.
17. Surviladze Z, Waller A, Wu Y, Romero E, Edwards BS, Wandinger-Ness A, et al. Identification of a smallGTPase inhibitor using a high-throughput flow cytometry bead-based multiplex assay. J Biomol Screen 2010;15:10-20.
18. Onesto C, Shutes A, Picard V, Schweighoffer F, Der CJ. Characterization of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. Methods Enzymol 2008;439:111-29.
19. Hong L, Kenney SR, Phillips GK, Simpson D, Schroeder CE, Noth, et al. Characterization of a Cdc42 protein inhibitor and its use as a molecular probe. J Biol Chem 2014;288:8531-43.
20. Surviladze Z, Young SM, Sklar LA. High-throughput flow cytometry beadbasedmultiplex assay for identification of Rho GTPase inhibitors.Methods Mol Biol 2012;827:253-70.
21. Kenney SR, Roxby J, Romero E, Ursu O, Oprea T, Sklar L, et al. Enantiomer specific inhibition of Rac1 and Cdc42 in ovarian cancer. Molec Biol Cell 2011;22:1363.
22. Muller C, Hudson LG, Kenney SR, Guo Y, Gaede M, Adams SF, et al. Rketorolac as aGTPase inhibitor: Phase 0 intraperitoneal pharmacokinetic and biologic activity in ovarian cancer patients. Gynec Oncol 2014;133:56S.
23. Oprea TI, Bauman JE, Bologa CG, Buranda T, Chigaev A, Edwards BS, et al. Drug Repurposing from an Academic Perspective. Drug Discov Today Ther Strateg 2011;8:61-9.
24. Guo Y, Kenney SR, Muller CY, Adams S, Rutledge T, Murray-Krezan C, et al. R-ketorolac targets Cdc42 and Rac1 and alters ovarian cancer cell behaviors critical for invasion and metastasis. Mol Cancer Ther molcanther. 0419.2015; Published OnlineFirst July 23, 2015; doi:10.1158/1535-7163.MCT-15-0419.
25. Forget P, Vandenhende J, Berliere M, Machiels JP, Nussbaum B, Legrand C, et al. Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. Anesth Analg 2010;110:1630-5.
26. Forget P, Bentin C, Machiels JP, Berliere M, Coulie PG, De Cock M. Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery. Br J Anaesth 2014;113(Suppl 1):i82-7.
27. Retsky M, Demicheli R, HrusheskyWJ, Forget P, De Kock M, Gukas I, et al. Reduction of breast cancer relapses with perioperative non-steroidal antiinflammatory drugs: New findings and a review. Curr Med Chem 2013;20:4163-76.
28. Mroszczak E, Combs D, Chaplin M, Tsina I, Tarnowski T, Rocha C, et al. Chiral kinetics and dynamics of ketorolac. J Clin Pharmacol 1996;36: 521-39.
29. Jett MF, Ramesha CS, Brown CD, Chiu S, Emmett C, Voronin T, et al. Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. J Pharmacol Exp Ther 1999; 288:1288-97.
30. Handley DA, Cervoni P, McCray JE, McCullough JR. Preclinical enantioselective pharmacology of (R)-and (S)-ketorolac. J Clin Pharmacol 1998;38:25S-35S.
31. Phenomenex, Phenomenex Chiral Column Protocols-online, App ID: 20367
32. Vakily M, Corrigan B, Jamali F. The problem of racemization in the stereospecific assay and pharmacokinetic evaluation of ketorolac in humans and rats. Pharm Res 1995;12:1652-57.
33. Buranda T, BasuRay S, Swanson S, Agola J, Bondu V, Wandinger-Ness A. Rapid parallel flow cytometry assays of active GTPases using effector beads. Anal Biochem 2013;442:149-57.
34. Hankey BF, Ries LA, Edwards BK. The surveillance, epidemiology, and end results program: A national resource. Cancer Epidemiol Biomarkers Pre 1999;8:1117-21.
35. Bast RC Jr,Hennessy B, Mills GB. The biology of ovarian cancer: New opportunities for translation. Nat Rev Cancer 2009;9:415-28.
36. Singh A, Karnoub AE, Palmby TR, Lengyel E, Sondek J, Der CJ. Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation. Oncogene 2004;23:9369-80.
37. Lee K, Chen QK, Lui C, Chicon MA, Radisky DC, Nelson CM. Matrix compliance regulates Rac1b localization, NADPH oxidase assembly, and epithelial-mesenchymal transition. Mol Biol Cell 2012;23:4097-108.
38. Liu J, Lee W, Jiang Z, Chen Z, Jhunjhunwala S, Haverty PM, et al. Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res 2012;22:2315-27.
39. Hayball PJ, Wrobel J, Tamblyn JG, Nation RL. The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. Br J Clin Pharmacol 1994;37:75-8.
40. LengR, LiaoG,WangH,Kuang J,TangL.Rac1expressioninepithelial ovarian cancer: Effect on cell EMT and cancer outcome. Med Oncol 2015;32:329.
41. Forget P, Machiels JP, Coulie PG, Berliere M, Poncelet AJ, Tombal B, et al. Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann Surg Oncol 2013;20(Suppl 3): S654-60.
42. Forget P, De KockM. Perspectives in anaesthesia for cancer surgery. J Cancer Res Clin Oncol 2014;140:353-9.
43. Inoue T, Murano M, Yoda Y, Kuramoto T, Kakimoto K, Ishida K, et al. Retodolac induces E-cadherin and suppresses colitis-related mouse colon tumorigenesis. Oncol Rep 2010;24:1487-92.
44. Yasui H, Hideshima T, Hamasaki M, Roccaro AM, Shiraishi N, Kumar S, et al. SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood 2005;106:706-12.
45. Kolluri SK, Corr M, James SY, Bernasconi M, Lu D, Liu W, et al. The Renantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Proc Natl Acad Sci U S A 2005;102:2525-30.
46. Feng R, Lentzsch S. Treatment of multiple myeloma with SDX-308. Drug News Perspect 2007;20:431-435.
47. Lindhagen E, Nissle S, Leoni L, Elliott G, Chao Q, Larsson R, et al. Retodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells. Cancer Chemother Pharmacol 2007;60:545-553.
48. Robak P, Smolewski P, Robak T. The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies. Leuk Lymphoma 2008;49:1452-62.
49. Yasui H, Hideshima T, Ikeda H, Ocio EM, Kiziltepe T, Vallet S, et al. Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of beta-catenin/TCF pathway. Leukemia 2007;21:535-40.
50. Gonzalez-Villasana V, Fuentes-Mattei E, Ivan C, Dalton HJ, Rodriquez-Aguayo C, Fernandez-de Thomas RJ, et al. Rac1/Pak1/p38/MMp-2 axis regulates angiogenesis in ovarian cancer. Clin Cancer Res 2015;21: 2127-37.